All attending UK organisations

UK companies attendingBIO-Europe Spring as part of the official delegation

(Click here to search profiles):

UK Exhibitors
BioPartner UK and the UK delegation: booth #6
SQN Clinical: booth #8
National Institute for Health Research (NIHR): booth #9

UK stand (booth 6) and Regional Groups:
Arcinova, Clinical Network Services (UK), Fusion Antibodies, Karma Oncology, LightOx, OBN (UK), Pebmond Associates, Phastar, Scottish Development International, UK Bioindustry Association.

Other UK companies associated with the delegation*:
Albumedix, Almac Discovery, AMR Centre, Aspire Pharma, BioAscent Discovery, Bit Bio Limited, C4X Discovery, Catalyst Advisors, Crystec, e Therapeutics, ERA Consulting, Ferghana Partners, Galen, Isogenica, LabGenius, LSX, Medherant, Mereo BioPharma Group, MGB Biopharma, Microbiotica, Midatech Pharma, Orbit Discovery, Oxstem, ProAxsis Limited, Sekisui, Silence Therapeutics, Sygnature Discovery, SYNthesis Research, Theradex Oncology, Tissue Solutions.

All attending UK companies:
AdisInsight, Albumedix, Almac Discovery, AMR Centre, Antev, Apex Healthcare Consulting, Arcinova, Arctoris, Arecor, Aspire Pharma, AstraZeneca, Asymchem Laboratories, Barrington James, BicycleTX, BioAscent Discovery, BioCentury, Biogen, BioPartner UK, BioPharma-Reporter, Bit Bio, Black Swan Analysis, C4X Discovery, Catalyst Advisors, Cello Health, Chiesi, Clarivate Analytics, Clinical Network Services (UK), Clinigen, Consilient Health, Coulter Partners, Covance, Crystec, cSubs, CV6 Therapeutics , Dementia Discovery Fund, Destiny Pharma, Domainex, e Therapeutics, EBD Academy, EBD Group, Eisai Europe, Eli Lilly and Company, Ellipses Pharma, Enplas Europe - CELL, ERA Consulting, Femtogenix, Ferghana Partners, Fujifilm Diosynth Biotechnologies UK, Fusion Antibodies, Galen, GlobalData, Goodwin, GSK, Healthcare at Home - Rare Disease Medicine Services, Hematherix, Histologix, Horton International UK, IAG, Iksuda Therapeutics, Inceptua, IN-PART, IONTAS, IQVIA Drug News, Isogenica, J A Kemp, Johnson & Johnson, Karma Oncology, Kymab, Kyowa Kirin Co, LabGenius, LGC, LightOx, Liminal BioSciences, LSX, Mallinckrodt Pharmaceuticals, Medherant, MedPharm, Mereo BioPharma, MGB Biopharma, Microbiotica, Midatech Pharma, Mission Therapeutics, Mitsubishi Tanabe Pharma Corporation, Mogrify, MSD, National Institute of Health (NIHR), Norgine Ventures, OBN (UK), One Nucleus, ONO pharma UK, Orbit Discovery, Otsuka Pharmaceutical, oval, Oxstem, Pebmond Associates, PharmaCircle, Pharmalicensing, pharmaphorum, PharmaVentures, Phastar, PhoreMost, Pracipio, ProAxsis, Proclinical, Quotient Sciences, Randox Biosciences, Sage Healthcare, Sanofi, SBA, Scius Communications, Scottish Development International, Sekisui, Silence Therapeutics, Simcere Pharmaceuticals, SmartAnalyst, Sosei Heptares, SQN Clinical, Sygnature Discovery, SYNthesis Research, The Fulford Group, The RSA Group, Theradex Oncology, Thermo Fisher Scientific, Tissue Solutions, Torreya, Transcrip Partners, UK Bioindustry Association, University of Edinburgh, Vaccitech, Veriton Pharma, Vernalis R&D, Virdis Group, Waracle, WuXi Biologics.
134 correct at 19/02/2010


Join them here!